Literature DB >> 19281539

Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases.

M Vasakova1, M Sterclova, L Kolesar, A Slavcev, P Pohunek, J Sulc, J Skibova, I Striz.   

Abstract

Idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP) and sarcoidosis belong to interstitial lung diseases (ILD) where an imbalance of regulatory, profibrotic and antifibrotic cytokines is hypothesized. The relationship of bronchoalveolar lavage (BAL) fluid (BALF) cytokines, BALF cell profile and ILD course is supposed. The aim of our study was to correlate BALF cytokine and chemokine levels with BALF cellular characteristics and lung function parameters in different ILD. Twenty-two sarcoidosis, seven IPF and 11 HP patients underwent lung function tests and BAL. The BALF differential cell counts and superficial cell markers were characterized, and MCP-1, MIP-1alpha, MIP-1beta, RANTES, epithelial neutrophil-activating protein (ENA)-78, FGF, G-CSF, GM-CSF, IFN-gamma, interleukin (IL)-1alpha, IL-1RA, IL-1beta, -2beta, -4beta, -5beta, -6beta, -8beta, -10beta, -17beta, tumour necrosis factor (TNF)-alpha, thromobopoietin (Tpo) and vascular endothelial growth factor (VEGF) values measured. The BALF VEGF values were highest in sarcoidosis (P = 0.0526). IL-1RA values were higher in IPF and HP compared with sarcoidosis (P = 0.0334). IL-8/ENA-78 ratio positively correlated with BALF neutrophil counts in IPF (r = 0.89, P = 0.04). Vital capacity and TL(CO) values positively correlated with VEGF and negatively with IL-8 BALF levels in all ILDs but the correlations were most significant in sarcoidosis group. We suppose that VEGF plays a role in ILDs' early phases and has rather angiogenic than profibrotic effect. On the contrary, IL-8 is probably upregulated in advanced ILDs with prominent fibrosis and marked lung functions decline. We state that BALF VEGF, IL-8 and ENA-78 levels and IL-8/ENA-78 ratio could become useful markers of ILDs' phase, activity and prognosis. They might also be helpful in treatment modality choice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19281539     DOI: 10.1111/j.1365-3083.2008.02222.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  27 in total

Review 1.  Bronchoalveolar lavage and other methods to define the human respiratory tract milieu in health and disease.

Authors:  Herbert Y Reynolds
Journal:  Lung       Date:  2011-02-25       Impact factor: 2.584

2.  Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report.

Authors:  Hyung-Joon Myung; Sook-Hyang Jeong; Jin-Wook Kim; Hee-Sup Kim; Je-Hyuck Jang; Ho Il Yoon; Jae-Sung Kim
Journal:  Gut Liver       Date:  2010-12-17       Impact factor: 4.519

3.  Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis.

Authors:  Matthew J Loza; Carrie Brodmerkel; Roland M Du Bois; Marc A Judson; Ulrich Costabel; Marjolein Drent; Mani Kavuru; Susan Flavin; Kim Hung Lo; Elliot S Barnathan; Robert P Baughman
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

Review 4.  Interstitial lung diseases in children.

Authors:  Annick Clement; Nadia Nathan; Ralph Epaud; Brigitte Fauroux; Harriet Corvol
Journal:  Orphanet J Rare Dis       Date:  2010-08-20       Impact factor: 4.123

Review 5.  Determinants of initiation and progression of idiopathic pulmonary fibrosis.

Authors:  Robert Matthew Kottmann; Christopher M Hogan; Richard P Phipps; Patricia J Sime
Journal:  Respirology       Date:  2009-09       Impact factor: 6.424

6.  Comparison of lymphocyte immune phenotypes in bronchoalveolar lavage of non-smoking patients with sarcoidosis and other interstitial lung diseases.

Authors:  Eva Novosadova; Zdenka Navratilova; Marta Ordeltova; Monika Zurkova; Jaromir Zatloukal; Vitezslav Kolek; Martin Petrek
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

7.  Effect of different interferonα2 preparations on IP10 and ET-1 release from human lung cells.

Authors:  Rekha Badiger; Jane A Mitchell; Hime Gashaw; Neil A Galloway-Phillipps; Stefan Foser; Fernando Tatsch; Thomas Singer; Trevor T Hansel; Tobias Manigold
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

Review 8.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

9.  Immune responses in the lungs of patients with tuberculous pleural effusion without pulmonary tuberculosis.

Authors:  Diana Qama; Won-Il Choi; Kun Young Kwon
Journal:  BMC Immunol       Date:  2012-08-13       Impact factor: 3.615

10.  Biomarkers of fibroproliferative healing in fibrosing idiopathic interstitial pneumonias.

Authors:  Martina Vasakova; Martina Sterclova; Eliska Stranska; Petra Mandakova; Jelena Skibova; Radoslav Matej
Journal:  Open Respir Med J       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.